Genenta Science SpA Sponsored ADR (GNTA) Price & Analysis

Compare

63 Followers

GNTA Stock Chart & Stats

$1.39

$0.22(4.52%)

At close: Jan 08 4:00 PM EST

$1.39

$0.22(4.52%)

Day’s Range― - ―

52-Week Range$1.35 - $10.00

Previous Close$5.5

Volume13.55K

Average Volume (3M)13.18K

Market Cap

$25.27M

Enterprise ValueN/A

Total Cash (Recent Filing)$17.67M

Total Debt (Recent Filing)$7.55M

Price to Earnings (P/E)―

Beta0.13

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.53

Shares Outstanding23,432,182

10 Day Avg. Volume11,250

30 Day Avg. Volume13,183

Financial Highlights & Ratios

PEG Ratio0.37

Price to Book (P/B)6.14

Price to Sales (P/S)0.00

P/FCF Ratio-12.29

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusModerate Buy

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical ProgressThe company's lead asset, Temferon, is advancing in first-line glioblastoma and has expanded into metastatic renal cell carcinoma, showing progress in its clinical programs.

Regulatory ApprovalGenenta recently received approval from the Agenzia Italiana del Farmaco (AIFA) to initiate this Phase 1 study in mRCC.

Safety ProfileIn the Phase 1/2a trial for glioblastoma, Temferon has been well tolerated with no dose-limiting toxicities, highlighting its safety profile.

Bears Say

Revenue DelaysTimelines for commercialization of Temferon have been pushed back to 2028 in Europe and 2029 in the US, indicating potential delays in revenue generation.

Genenta Science SpA Sponsored ADR News

Genenta Science provides update from TEM-GBM study

Genenta Science (GNTA) announced an update from its ongoing TEM-GBM study in newly diagnosed glioblastoma multiforme patients with...

25d ago

GNTA

Genenta Science Expands Board and Corporate Purpose Following Shareholders’ Meeting

Genenta Science SpA Sponsored ADR ( ($GNTA) ) just unveiled an update. On October 29, 2025, Genenta Science...

2M ago

GNTA

Genenta Science Secures $15 Million in Registered Direct Offering

An announcement from Genenta Science SpA Sponsored ADR ( ($GNTA) ) is now available. On October 26, 2025,...

2M ago

GNTA

Genenta Science Appoints New Board Member and Confirms CEO

Genenta Science SpA Sponsored ADR ( ($GNTA) ) has shared an update. On April 29, 2025, Genenta Science...

2M ago

GNTA

Morning News Wrap-Up: Friday’s Biggest Stock Market Stories!

Earnings reports, analyst updates, inflation data, and more make up some of the top stock market headlines for Friday. ...

2M ago

AMD

Why Is Genenta Science Stock (GNTA) Up 275% Today?

Genenta Science stock surged on Friday after it announced an expanded strategic partnership. ...

2M ago

GNTA

Genenta Science, Anemocyte enter pact to advance Plasmid DNA technology

Genenta Science (GNTA) and Anemocyte announced a strategic collaboration with a focus on off-the-shelf lentiviral vector Plasmid DNA...

2M ago

GNTA

Genenta Science Reports Reduced Losses and Strengthened Balance Sheet for H1 2025

Genenta Science SpA Sponsored ADR ( ($GNTA) ) has provided an announcement. Genenta Science S.p.A. reported its financial...

2M ago

GNTA

Leadership Change at Genenta Science SpA: Dr. Galimi Appointed Acting CMO

Genenta Science SpA Sponsored ADR ( ($GNTA) ) has shared an update. On September 30, 2025, Genenta Science...

3M ago

GNTA

Genenta Science S.p.A. Announces Shareholders’ Meeting for Strategic Amendments

The latest announcement is out from Genenta Science SpA Sponsored ADR ( ($GNTA) ). On September 10, 2025,...

3M ago

GNTA

Genenta Science S.p.A. to Terminate Dedicated Suite Agreement with AGC Biologics

Genenta Science SpA Sponsored ADR ( ($GNTA) ) just unveiled an announcement. On December 30, 2024, Genenta Science...

5M ago

GNTA

Promising Long-Term Data and New Trials Bolster Genenta Science’s Buy Rating

Genenta Science SpA Sponsored ADR, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst...

6M ago

GNTA

Genenta Science announces follow-up observations in glioblastoma study

Genenta Science (GNTA) announced that a total of 38 patients were enrolled in newly diagnosed glioblastoma multiforme study,...

6M ago

GNTA

Genenta Science, Anemocyte announce collaboration

Genenta Science (GNTA) announced a collaboration with Anemocyte. This strategic partnership marks a major milestone, encompassing the successful...

8M ago

GNTA

GNTA FAQ

What was Genenta Science SpA Sponsored ADR’s price range in the past 12 months?

Genenta Science SpA Sponsored ADR lowest stock price was $1.35 and its highest was $10.00 in the past 12 months.

What is Genenta Science SpA Sponsored ADR’s market cap?

Genenta Science SpA Sponsored ADR’s market cap is $25.27M.

When is Genenta Science SpA Sponsored ADR’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Genenta Science SpA Sponsored ADR’s earnings last quarter?

Currently, no data Available

Is Genenta Science SpA Sponsored ADR overvalued?

According to Wall Street analysts Genenta Science SpA Sponsored ADR’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Genenta Science SpA Sponsored ADR pay dividends?

Genenta Science SpA Sponsored ADR does not currently pay dividends.

What is Genenta Science SpA Sponsored ADR’s EPS estimate?

Genenta Science SpA Sponsored ADR’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Genenta Science SpA Sponsored ADR have?

Genenta Science SpA Sponsored ADR has 23,432,182 shares outstanding.

What happened to Genenta Science SpA Sponsored ADR’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Genenta Science SpA Sponsored ADR?

Currently, no hedge funds are holding shares in GNTA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Genenta Science SpA Sponsored ADR

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. The company was incorporated in 2014 and is headquartered in Milan, Italy.